Feladilimab Biosimilar – Anti-ICOS mAb – Research Grade from ProteoGenix; catalogue PX-TA1667; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Feladilimab Biosimilar is a novel monoclonal antibody (mAb) that specifically targets the inducible T cell co-stimulator (ICOS) protein. This biosimilar is a highly promising therapeutic agent for the treatment of various inflammatory and autoimmune diseases. In this article, we will delve into the structure, activity, and potential applications of Feladilimab Biosimilar.
Feladilimab Biosimilar is a recombinant humanized IgG1 monoclonal antibody that is produced using advanced biotechnological techniques. It is composed of two heavy chains and two light chains, each with a molecular weight of approximately 150 kDa. The heavy chains consist of four constant regions (CH1, CH2, CH3, and CH4) and one variable region (VH), while the light chains consist of two constant regions (CL) and one variable region (VL).
The unique feature of Feladilimab Biosimilar is its high specificity for the ICOS protein. This specificity is achieved through the use of a humanized antibody that is engineered to have a high affinity for the ICOS protein. This allows for precise targeting of the ICOS protein, minimizing the risk of off-target effects.
The primary activity of Feladilimab Biosimilar is its ability to bind to the ICOS protein. ICOS is a co-stimulatory molecule that is expressed on the surface of activated T cells. It plays a crucial role in regulating T cell activation and differentiation, making it an attractive therapeutic target for inflammatory and autoimmune diseases.
By binding to the ICOS protein, Feladilimab Biosimilar blocks its interaction with its ligand, ICOSL. This disrupts the co-stimulatory signal that is required for T cell activation and proliferation. As a result, the immune response is dampened, leading to a reduction in inflammation and tissue damage.
Feladilimab Biosimilar also has the potential to modulate the function of regulatory T cells (Tregs). Tregs are a subset of T cells that play a crucial role in maintaining immune tolerance and preventing autoimmune diseases. By targeting the ICOS protein, Feladilimab Biosimilar may enhance the suppressive function of Tregs, further dampening the immune response.
Feladilimab Biosimilar has shown great promise in preclinical studies for the treatment of various inflammatory and autoimmune diseases, including rheumatoid arthritis, psoriasis, and multiple sclerosis. Its high specificity and potent activity make it a promising therapeutic agent for these conditions.
In addition to its potential as a standalone therapy, Feladilimab Biosimilar also has the potential to be used in combination with other immunomodulatory agents. For example, it may be used in combination with checkpoint inhibitors to enhance their efficacy in cancer treatment. By targeting the ICOS protein, Feladilimab Biosimilar may also overcome resistance to checkpoint inhibitors, making it a valuable addition to cancer treatment regimens.
In summary, Feladilimab Biosimilar is a highly promising anti-ICOS monoclonal antibody with a unique structure and potent activity. Its potential applications in the treatment of various inflammatory and autoimmune diseases make it an exciting prospect for the future of immunotherapy. Further clinical studies are needed to fully explore the therapeutic potential of this revolutionary biosimilar.
Keywords: Feladilimab Biosimilar, anti-ICOS mAb, therapeutic target, inflammatory diseases, autoimmune diseases, immunotherapy
ProteoGenix catalogue number PX-TA1667. For research use only.
Target: Feladilimab Biosimilar – Anti-ICOS mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Purity: >85%; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Feladilimab Biosimilar – Anti-ICOS mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
